Gilead Sciences announced that the European Commission has granted marketing authorization for Yeytuo (lenacapavir), the ...

We recently published Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings. Gilead Sciences Inc (NASDAQ:GILD) is one of ...

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV ...

A federal judge has recused herself from a criminal case involving a scheme to sell counterfeit HIV drugs on the black market ...

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

The European Commission has approved Gilead’s lenacapavir, a twice-yearly HIV prevention injection, offering high-risk individuals a long-acting alternative and expanding access ...

Investing.com -- Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its ...

Kite Pharma will buy Interius BioTherapeutics for $350 million in cash to add an in vivo CAR‑T platform that creates T‑cell ...

Gilead Sciences (GILD) stock in focus as its twice-yearly HIV PrEP therapy lenacapavir, is approved in the EU as Yeytuo for HIV prevention. Read more here.

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...